The Laminin 511/521 Binding Site on the Lutheran Blood Group Glycoprotein is Located at theFlexible Junction of Ig Domains 2 and 3 by Mankelow, Tosti J. et al.
 1 
THE LAMININ 511/521 BINDING SITE ON THE LUTHERAN 
BLOOD GROUP GLYCOPROTEIN IS LOCATED AT THE 
FLEXIBLE JUNCTION OF Ig DOMAINS 2 AND 3. 
 
Tosti J. Mankelow1,7, Nicholas Burton2,7, Fanney O. Stefansdottir1, Frances A. Spring1, 
Stephen F. Parsons1, Jan S. Pedersen3, Cristiano L.P. Oliveira3, Donna Lammie4, 
Timothy Wess4, Narla Mohandas5, Joel A. Chasis6, R. Leo Brady2 and David J. Anstee1. 
 
 
1Bristol Institute for Transfusion Sciences, National Blood Service, Bristol, UK.  
2Dept of Biochemistry, University of Bristol, Bristol, UK.  
3Department of Chemistry, University of Aarhus, Aarhus, Denmark 
4School of Optometry and Vision Sciences, Cardiff University, Cardiff, UK.  
5New York Blood Center, New York, NY 10021, USA.  
6University of California, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, 
USA 




Short title: Molecular basis of Lutheran binding to Laminin. 
 
Scientific category: Red Cells 
 
Presented in part as an abstract to the 48th Annual meeting of the American Society of 
Hematology, Orlando FL December 9-12 2006 
 
Address correspondence to:  
 
R. Leo Brady, Department of Biochemistry, University of Bristol, Bristol BS8 1TD U.K.; Tel. 
+44(0)117 117 331 2150; Fax +44(0)117 117 331 2168; Email: L.Brady@bris.ac.uk. 
Tosti J Mankelow, BITS, Southmead Road, Bristol, BS10 5ND, UK; Tel +44(0)1179912123; 
Fax +44(0)1179591660, Email: tosti.mankelow@nbs.nhs.uk 
 
Keywords: Extracellular matrix / Lutheran glycoprotein / Laminin / sickle cell disease / X-
ray crystallography. 
 
Abbreviations used: ECM, Extracellular matrix; Lu gp, Lutheran glycoprotein; Lu gpFc, 
Lutheran glycoprotein Fc fusion protein; Ln, Laminin; Ln511/521, Laminin 511/521; LG, 




Abstract Word Count 185 
Total Word Count:4960 
 2 
Abstract 
The Lutheran blood group glycoprotein, first discovered on erythrocytes, is 
widely expressed in human tissues. It is a ligand for the α5 subunit of Laminin 
511/521, an extracellular matrix protein. This interaction may contribute to 
vasocclusive events that are an important cause of morbidity in sickle cell 
disease. Using X-ray crystallography, small angle X-ray scattering and site 
directed mutagenesis we show that the extracellular region of Lutheran forms an 
extended structure with a distinctive bend between the second and third 
immunoglobulin-like domains. The linker between domains 2 and 3 appears to 
be flexible and is a critical determinant in maintaining an overall conformation 
for Lutheran that is capable of binding to Laminin. Mutagenesis studies indicate 
that Asp312 of Lutheran and the surrounding cluster of negatively charged 
residues in this linker region form the Laminin binding site. Unusually, receptor 
binding is therefore not a function of the domains expected to be furthermost 
from the plasma membrane. These studies imply that structural flexibility of 
Lutheran may be essential for its interaction with Laminin and present a novel 




The Lutheran glycoprotein (Lu gp) cellular adhesion molecule is widely expressed in 
human tissues1 and is known for carrying antigens of the Lutheran blood group 
system. On erythrocytes Lu gp is expressed as two isoforms of 78 and 85kDa2. Both 
share a common extracellular portion which has previously been predicted to 
comprise 5 immunoglobulin superfamily (IgSF) domains1. The 78kDa isoform (also 
known as BCAM3 or Lu[v13]4) results from alternative splicing and lacks 40 C-
terminal amino-acids within the cytoplasmic domain which contain an SH3 binding 
motif, a dileucine motif responsible for basolateral targeting5 and five potential 
phosphorylation sites1.  
 
Lu gp binds specifically and with high affinity to the extracellular matrix (ECM) 
protein Laminin (Ln) containing the α5 subunit6-9 (Laminin 511 and Laminin 521 
(Ln511/521) (numbering as in10). This interaction plays a direct role in the 
pathophysiology of sickle cell disease by mediating adhesion of sickle cells, via Lu 
gp, to exposed Ln511/521 of inflamed or damaged vascular endothelium9,11,12. Recent 
studies have shown that higher than normal intracellular levels of cAMP in sickle 
erythrocytes influence a protein kinase A mediated or Rap1-mediated signalling 
pathway resulting in increased adhesion of sickle cells to the basement membrane 
glycoproteins Ln511/52113,14. Furthermore, phosphorylation of the 85kDa Lu gp at 
S621 in epinephrine stimulated K562 cells alters adhesion to Ln511/52115. 
 
The Ln binding activity of Lu gp is a property of the amino terminal region of Lu gp, 
and has been localised to a region predicted to form the first three IgSF domains 
(D1D2D3)6,16. The complementary binding site on Ln is located within a large 
carboxyl-terminal globular domain of the α5 subunit, known to comprise five 
Laminin-type G (LG) modules, LG1 to LG517,18. These modules, present at the 
carboxy termini of all Ln α chains, have also been shown to regulate binding to at 
least 6 integrins18-20 in addition to α-dystroglycan and heparin21-23. Binding to the 
latter two ligands results from positively charged residues on Ln and regions of 
negative charge (acidic sugar residues) on heparin and α-dystroglycan24,25. 
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Here we use a multidisciplinary approach to explore the molecular basis of the 
interaction between Lu gp and Ln511/521. We describe the elucidation of a structure 
for the Ln binding portion of the Lu gp molecule. This structure comprises a high 
resolution crystal structure for domains 1 and 2 (D1D2) to which has been added a 
predicted model for domain 3 (D3) by fitting to a molecular envelope calculated from 
small-angle X-ray scattering (SAXS) data. The location of these domains within the 
overall extracellular form of Lu is also demonstrated by SAXS. Secondly, site-
directed mutagenesis has been used to examine residues suspected to be involved in 
the interaction with Ln. This led to the identification of amino-acid residues 
comprising the Ln511/521 binding site on Lu gp. An unexpected finding is that, 
unlike most cell-cell interactions that characteristically result from the formation of 
cell adhesion pairs between the membrane-distal domains of cell adhesion molecules 
(e.g. CD2:CD5826 and CD2:CD4827), Lu gp uses a more membrane-proximal inter-
domain junction region to form a critical part of its Ln binding site. 
 
Materials and Methods 
 
Synthesis, purification and crystallisation of Lu gp 
 
The extracellular domains of human Lu gp were expressed as Fc fusion proteins in 
NS0 cells using the procedures as described28. Residues 1-330 (D1D2D3), residues 1-
515 (Lu gp), were included in the expressed proteins, immediately followed at the C-
terminus by the Tobacco Etch Virus protease (TEV) cleavage site VDENLYFQG and 
human IgG Fc immunoglobulin fragment. Secreted fusion proteins were purified from 
cell supernatant using Protein A Sepharose and the Fc fragment was liberated by 
digestion with recombinant TEV (Invitrogen, Paisley, UK) and removed on Protein A 
Sepharose.  
 
The D1D2 fragment was liberated by chymotrypsin digestion of the purified 
D1D2D3, using a 1:100 enzyme:Lu ratio at pH7.4 for 18 hours at 18ºC. 
Chymotrypsin was removed with a benzamidine column (Amersham Biosciences) 
prior to a final gel filtration purification step (HiLoad 16/60, Superdex 75 prep grade, 
Amersham Biosciences). 
 
For crystallisation trials proteins were concentrated to 8mg/ml in 20mM HEPES pH 7 
buffer. Diffraction quality hexagonal crystals were grown from a mother liquor 
containing 18% (w/v) PEG4000, 0.1M sodium citrate (pH5.6), 0.2M ammonium 
acetate. A second monoclinic crystal form was obtained from 12% (w/v) PEG20000, 
0.1M MES (pH 6.4), 6% (w/v) hexane-1,2-diol. Heavy atom derivatives of crystals 
were prepared by soaking in well solutions supplemented with either 10mM 
potassium tetrachloro platinate (II) for 24h or 100mM potassium dicyanoaurate (I) for 
72h. Diffraction data were collected at the Daresbury SRS synchrotron on beamlines 
14.1 and 10.1 (see Table 1). Crystals of the monoclinic form (one molecule per 
asymmetric unit) generally produced higher quality diffraction data and were used for 
the experimental phase determination. Heavy atom sites were located with SHELXD29 
and refined with MLPHARE30. Density modification was performed using DM30 and 
ARP/wARP31. The model was refined against the native amplitudes and experimental 
phases using REFMAC530. The hexagonal crystal form was solved by molecular 
replacement using PHASER32 using separate domains from the monoclinic structure 
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as search models. The structure was initially refined with CNS33, using a simulated 
annealing protocol, then fully refined with REFMAC5. The validity of the structures 
was assessed with MOLPROBITY34. Refinement statistics are summarised in Table 1.  
 
Lu gp D3 homology model 
 
Sequence comparisons indicated that D3 was most similar to the Ig3 domain of 
perlecan (PDB ID 1gl4, chain B35), a known I-set IgSF domain, and this was used as 
the structural template for the model of D3. Sequences were aligned with ClustalW 
and adjusted manually; secondary structure was predicted with the Jpred36,37 and 
SAMT0238servers. The sequence alignment and secondary structure predictions were 
used as input for Modeller39 to generate the three-dimensional model. 
 
Small-Angle X-ray scattering analysis  
 
Full SAXs methods can be found as Supplementary Data 1. Briefly, SAXS data of 
D1D2D3 were collected on beamline X33 at the European Molecular Biology 
Laboratory (EMBL) of the Deutsches Elektronen Synchrotron (DESY) using a 
wavelength of λ=0.15nm, covering a scattering range of 0.16nm-1<q<4.85nm-1, where 
q=4π sinθ/λ; 2θ is the scattering vector. Sample concentrations were 4.375 mg/ml, 
8.75mg/ml and 17.5mg/ml; samples were supplemented with 1mM dithiothreitol and 
exposed for 60s, scattering data from the buffer solution was also collected. The 
scattering images were integrated to one-dimensional linear profiles using in-house 
software at station X33. Scattering data were processed with the ATSAS2.1 software 
suite as previously described40. 
 
SAXS data for the entire extracellular portion of Lu (D1-D5) were collected using the 
modified version of a NanoSTAR (Bruker AXS, Karlsruhe) at the University of 
Aarhus, see41 for details. The sample concentration was 15mg/ml and the scattering 
range was 0.085<q<3.5nm–1. The two-dimensional data were azimuthally averaged to 
one-dimensional linear profiles using Bruker SAXS software. Data was processed as 
above, except that buffer scattering subtraction and transformation to absolute units 
using the scattering of water as a standard was performed with in-house software at 
the University of Aarhus.  
 
Preparation of mutant and native Lu gp Fc fusion proteins (Lu gpFc) 
 
Point mutations were inserted into human Lu gp cDNA clones42 encoding the five 
extracellular domains in pIg vector by PCR amplification as described43. Mutant 
clones were confirmed by DNA sequence analysis. Native and mutant Lu gpFc and 
Muc-18 Fc (a gift from Dr Simmons (Glaxo SmithKline, Harlow, UK) were 
expressed in COS-7 cells, purified using protein A-Sepharose and quantified as 
described43. 
 
Lu gp binding Ln511/521 ELISA  
 
Washes and protein dilutions were performed in phosphate-buffered saline with 0.2% 
bovine serum albumin (assay buffer). All protein dilutions were added in 50µl and 
incubations were at 37oC with shaking for one hour unless stated otherwise. Immulon-
4 96 well plates (Dynes Technologies, West Sussex, UK) were coated with 
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0.25µg/well goat-anti-human-Fc (Jackson ImmunoResearch, Cambridgeshire, UK) in 
0.1M bicarbonate buffer, pH 9.6 for 24 hours at 4oC. After three washes 5, 0.5, 0.05 
and 0.005nM native or mutated Lu gpFc was added and the plate incubated. After one 
wash the plate was blocked for 30 minutes at room temperature in assay buffer 
containing 5% human AB serum followed by one wash. Ln511/521 (Chemicon, 
Hampshire, UK) at 5nM was added and the plate incubated. After three washes a 1 in 
100 dilution of rabbit anti-laminin (Sigma, Dorset, UK) was added, the plate 
incubated and after three washes a 1 in 1000 dilution of horse radish peroxidase 
linked swine anti-rabbit (DAKO, Cambridgeshire, UK) was added, incubated and 
washed a further three times. The plate was developed using 3,3',5,5'-
Tetramethylbenzidine and 3% H2O2 in 0.1M acetate/citrate buffer pH6, stopped with 
2M H2SO4 and read at 450nm. The ELISA was controlled by coating wells with 5nM 
Ln511/521 and by addition of 5nM Ln511/521 to captured Muc18 Fc. 
 
Surface Plasmon Resonance Assays  
 
All assays were performed at 25oC using a Biacore X, a CM5 chip with protein A 
immobilised on its surface and a flow rate of 30µl per minute. Running buffer was 
phosphate buffered saline pH 7.4 containing 0.05% Tween 20 and regeneration buffer 
was 0.1M glycine pH 2. Native or mutant Lu gpFc was captured onto the chip until a 
change of 40 response units was observed (0.25pm). Ln511/521 was added in a 100µl 




Crystal structure of Lu gp D1D2 
 
Extensive attempts to crystallise fragments of Lu gp comprising either all three N-
terminal domains (residues 1-330) or the entire extracellular region were 
unsuccessful, consistent with innate molecular flexibility in Lu gp. Instead, a stable 
fragment of Lu gp consisting of domains 1 and 2 (D1D2) was produced by 
chymotryptic digestion of the three-domain construct. This fragment was purified and 
crystallised in two crystal forms (Table 1). In the refined crystal structures the 
asymmetric unit of the monoclinic form contains one molecule, whereas there are two 
molecules in the hexagonal asymmetric unit. Together these provide three separate 
views of Lu gp D1D2. Coordinates and structure factors for the D1D2 crystal 
structures are available from the Protein Data Base (accession codes 2PET 
(monoclinic form) and 2PF6 (hexagonal form)). 
 
The crystal structures show the amino terminal portion of Lu gp consists of two IgSF 
domains (Figure 1) which together form a monomeric straight rod approximately 85Å 
long and 25Å wide. There is limited flexibility between the two domains, the relative 
positions of which are seen to vary by up to 12° when the three non-identical 
molecules from the two crystal forms are compared (Figure 1b). Domain 1 (D1) is 
formed from residues 1-111 and is, as predicted, a member of the V-set of 
immunoglobulin domains (Supplementary Data 2). It contains the conserved 
disulphide bond between strands B and F, each of the B/C, C’/C” and F/G loops – the 
equivalent of complementarity determining loops in the antibody V-domains – are 
relatively short. The C/C’ loop projects away from the body of the domain and 
appears to be primarily held in this orientation by a salt bridge formed between Arg44 
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and Glu105. The base of the domain is intimately associated with domain 2 (D2). The 
domains are linked by a short run of hydrophobic amino-acids (112Val-Phe-Ala114) 
which are buried within the interface. Unexpectedly D2 (residues 115-229) lacks A´, 
C´ and C´´ strands ruling out its original sequence-based classification as a V-set 
domain (Supplementary Data 2). Despite the increased length of the polypeptide chain 
in this domain it is most like a C1-set domain, unusual outside of immune system 
proteins. The additional residues are incorporated primarily within extended A/B, C/D 
and E/F loops, all of which are at the base of the domain. One notable feature is the 
presence of a short helical segment within the E/F loop. All of these features lead to 
an extended surface at the C-terminal end of the domain, which lies adjacent to the 
interface with D3. 
 
The 18 identified antigens of the Lutheran blood group system are predominantly 
associated with single-nucleotide polymorphisms resulting in single amino-acid 
changes within Lu gp44. A study of 11 of these antigens revealed that in 7 cases these 
changes could be located to residues in D1 or D244, the sites of which may now be 
visualised (Figure 1c). The prevalence of these changes in the two amino-terminal 
domains is consistent with their ready exposure at the cell surface, implying that they 
may lie furthermost from the membrane. These allelic changes appear to be 
distributed across all of the available faces of D1D2 and all occur at surface exposed 
regions including both loop and sheet locations. In all cases the observed amino-acid 
changes are not expected to be deleterious for the overall Lu gp structure.  
 
Construction of an homology model for D3 
 
Chymotryptic digestion of D1D2D3 consistently resulted in proteolysis of D3, 
preventing an experimental determination of its structure. We therefore constructed a 
molecular model of D3 (residues 236-324), based on its sequence homology with 
known I1-set domains. Note that this differs from the original classification of D3 as a 
C2-set domain1. The two single-point mutations (S244 and T271) associated with D3 
inherited blood group antigens (LU6/LU9 and LU20) were both found to be located 
on the surface of the final model, an assumption not made throughout the modeling 
process. 
 
SAXS analysis of Lu gp  
 
In order to delineate the placement of D3 with respect to D1D2 we performed a 
SAXS analysis of the D1D2D3 construct. Two methods were used to independently 
derive an overall conformation of D1D2D3. Firstly, the scattering data (Figure 2a) 
were fitted with ab initio bead models using two separate programs, DAMMIN45 and 
GASBOR46. In each case chi values of ≈1.9 were obtained, and both methods 
generated very similar hockey-stick shapes (Figure 2b). The chi value is a measure of 
the discrepancy between the experimental data and the theoretical scattering generated 
by the model, a good fit should return a value <3 (with absolute equivalence =1). 
Secondly, the crystal structures of Lu gpD1D2 and the model of D3 were fitted as 
separate rigid bodies to the scattering data using the software SASREF47. The 
resulting chi values ranged from 1.7-1.9. All three crystal structures of D1D2 gave 
similar results. When superimposed the individual fits show very similar gross 
conformations with a significant bend angle between domains 2 and 3 (Figure 2c), 
although the exact orientation of D3 with respect to D2 is insufficiently defined to 
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assign a single unique conformation. Similarly, the conformation of the D2–D3 linker 
peptide is not distinguished in this analysis. 
 
A similar SAXS analysis was also performed on the overall Lu gp (D1-D5) construct. 
It is evident from the calculated envelopes and shapes that Lu gp forms an extended 
structure with a distinctive bend to one side of the mid-region (Figure 2d). The 
derived D1D2 and D1D2D3 structures overlay well at one end of this shape (Figure 
2e). Domains 4 and 5 are also expected to adopt IgSF fold, however, due to limited 
experimental evidence we feel it would be too speculative to include them in our 
model. Nonetheless, their approximate placement relative to D1D2D3 is evident. 
 
Mutagenesis of acidic residues on D2 and D3 diminishes Ln511/521 binding 
 
Using full-length Lu gp in an ELISA we found that the Lu gp-Ln511/521 interaction 
is pH dependent, occurring only in the range between pH5 and 10. We also confirmed 
the interaction is inhibited in the presence of high salt (1M NaCl)17 (data not shown). 
The dependence on pH and salt concentration is consistent with charged or polar 
interactions regulating the binding of the two molecules. There are known areas of 
positively charged amino-acids on LG domains so we hypothesised that negatively 
charged residues on Lu gp would be responsible for Ln binding. This is consistent 
with the observations that interactions between positively charged residues on Ln and 
negative charges on both heparin and α-dystroglycan provide the basis for these 
molecular interactions24,25. Analysis of an homology model of Lu gp initially allowed 
us to target surface-exposed clusters of aspartic and glutamic acid residues for 
mutation; the precise locations of acidic residues on D2 were subsequently 
demonstrated by the crystal structures. The majority of residues selected are 
conserved or identical in the mouse Lu gp homologue. Each mutant Lu gp was 
detected by Western blotting with monoclonal anti-Lu (BRIC 221 and BRIC 224) and 
an anti Fc antibody (Supplementary Data 3). Since the epitopes for BRIC 221 and 224 
are conformationally dependent and are destroyed in reducing conditions, these 
results show none of the mutations markedly altered the structure of Lu gpFc. 
 
The Ln511/521 binding properties of the thirteen mutant Lu proteins were examined 
by an ELISA using four Lu gp coating concentrations. Over the complete range of Lu 
gpFc concentrations the D312A mutation caused a severe reduction in Ln511/521 
binding, E309A and D310A showed a marked reduction, whereas E132A/D133A, 
D198A/D199A, E269A, D280A and D316A caused only a slight decrease in binding 
(Figure 3a (Supplementary Data 4). At 0.05nM the native Lu gp was exposed to 
saturating amounts of Ln511/521 so this concentration was used to determine the 
different levels of adhesion to Ln511/521 of the various Lu gp mutants (Figure 3b 
(Supplementary Data 4). All other mutant proteins had the same or similar levels of 
binding to Ln511/521 as that obtained with native Lu gpFc (Figure 3b). 
 
The mutant proteins were also assayed for Ln511/521 binding using a Biacore X 
(Figures 3c and d) and sensorgrams showed the effect caused by each mutation is 
similar to that observed by ELISA (Figures 3a and b). The Biacore assays indicate 
that mutations affecting Ln511/521 binding slow the rate at which Ln511/521 binds to 
Lu gpFc whereas the rate at which Ln511/521 dissociates is not affected (Figure 3c). 
Compared to our earlier study6 the rate of dissociation of Lu gpFc and Ln511/521 is 
somewhat slower. In the previous published study6 an Iasys optical biosensor and a 
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different source of Ln511/521 was used making direct comparisons between the two 
studies difficult. Association and dissociation of Lu gp and the Ln511/521 used in this 
study was measured on the BiacoreX using Ln511/521 injections at 50nM, 20nM, 
10nM, 5nM and 2nM and the calculated KD was 7.2nM which is comparable to 
previously reported values (7.9nM6 and 10.8nM16). It was not possible to obtain a set 
of binding curves to calculate KD for the mutant forms of Lu gp that showed a 
reduction in Ln binding because of the constraints of the limited availability and 
solubility of Ln511/521.  
 
The results show E132A/D133A, D198A/D199A, E269A, D316A and to a much 
greater extent E309A, D310A and D312A, inhibit Ln511/521 binding to Lu gp. These 
residues cluster within the A/B and E/F loops at the base of D2 and B/C and F/G 
loops at the top of D3. The location and importance of each amino-acid is depicted in 
Figure 4. 
 
Mutagenesis of the D2-D3 linker affects Ln511/521 binding 
 
The results of site-directed mutagenesis described above are consistent with previous 
studies which used domain-deletion mutants of Lu gp to show that the binding site for 
Ln511/521 is within the first three domains6,16. Despite containing key residues 
involved in binding Ln511/521 Lu gp proteins containing D2 without D3, and more 
significantly, D3 without D2 were unable to support binding of Ln511/5216,16. The 
observation that both D2 and D3 are required for Ln511/521 binding raises the 
question of the importance of the linker or hinge sequence between D2 and D3 in 
defining the structure of Lu gp. We constructed two Lu gpFc mutants in which 
residues in the hinge were replaced with a proline (T233P and H235P) and a third 
mutant that had three residues removed from the hinge (∆233-235) (Figure 5a). 
Western blotting with BRIC 221 and 224 confirmed these molecules were folded 
correctly (Supplementary Data 3). Ln511/521 binding by mutant T233P was 
markedly reduced and that of H235P and ∆233-235 was abolished (Figures 4b and c). 
Interestingly, even at high Lu gpFc concentrations in the ELISA the ∆233-235 
mutation did not bind Ln511/521 (Figure 5b). These data are consistent with an 
essential role for the linker region in allowing D2 and D3, and the rest of the Lu gp 
molecule, to adopt a conformation capable of binding Ln511/521. 
 
Taken in their entirety these mutagenesis data suggest the primary binding site for the 
Ln α5 chain is defined by negatively charged residues at the top of D3 and to a lesser 
extent at the base of D2. An appropriate presentation of both D2 and D3 for 





Ln has previously been shown to bind to its other ligands (heparin, α-dystroglycan) 
via positively charged basic residues on the LG domains adhering to areas of negative 
charge on its ligands21,22. The results presented here are consistent with a similar 
mechanism for the Ln α5 chain-Lu gp interaction. Inspection of the crystallographic 
structures of D1D2 and the model of D3 of Lu gp revealed dominant areas of negative 
electrostatic potential that we hypothesised form the Ln binding site. Many of the 
acidic residues in this region are conserved in the murine homologue that also binds to 
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human Ln511/5216. When negatively charged residues in the patch were mutated to 
alanine and the mutant proteins assessed for Ln511/521 binding by both ELISA and 
Biacore assay, residue D312 and, to a lesser extent, E309 and D310 were identified as 
critical residues. Other negatively charged residues in the vicinity of these three also 
had small effects on binding. When the positions of all the mutations made in this 
study are mapped to the crystallographic structure of D2 and the homology model of 
D3 those that affect the binding to Ln511/521 form a cluster at the domain interface 
(Figure 4), with the single exception of E180, the mutation of which caused an effect 
only in the surface plasmon resonance assay and not the ELISA. In the orientation of 
the D1D2D3 structure, along with the D1-D5 structure, shown in Figure 4 this cluster 
corresponds to a protrusion formed by the bend between D2 and D3, akin to a spur on 
the heel of a boot. We speculate that the negative charge on D312 interacts with a 
positively charged amino-acid on the Ln α5 chain and that this charged interaction is 
the primary determinant of adhesion between the two molecules. The other acidic 
amino-acids identified here could potentially produce a localised negative charge on 
Lu gp around D312 and facilitate docking by interaction with other positive charges 
on the Ln α5 chain. The close homology between the sequence of human and murine 
Lu gp6 suggests that murine Lu gp has a similar structure to its human counterpart and 
binds Ln511/521 in an identical manner.  
 
Our results demonstrate not only that the binding site for the Ln α5 chain is defined 
by negatively charged residues on D2 and D3 but also that the linker region between 
these domains is critical for binding. The approximately eight amino-acids that 
comprise the link between D2 and D3 are likely to have an open conformation as 
evidenced by the susceptibility of this region to proteolysis and by SAXS analysis that 
shows that the Lu gp structure is non-linear in this region. Unlike at the D1D2 
junction, these residues are not predominantly hydrophobic (HYPTEHVQ) indicating 
the linker is unlikely to be buried within a tight interdomain interface. We have also 
shown that by placing a proline in this linker region (H235P) or by removing 3 
amino-acids (∆233-235) and shortening the linker, Lu gp binding to Ln511/521 is 
totally abolished. These data could be interpreted as indicating residues T233, E234 
and H235 are directly involved in binding to Ln511/521. However, this seems 
unlikely since mutation of E234A has only a minor effect on binding (Figure 3a and 
b). It is more plausible that in order to adhere to the Ln α5 chain Lu gp D1D2 needs 
to be in a suitable spatial orientation relative to D3 and possibly also the stem formed 
by D4 and D5. 
 
One interpretation of an extended conformation at the D2/D3 interface is that this 
region is likely to exhibit inter-domain flexibility. Although the crystal structures also 
show a degree of flexibility at the D1/D2 interface, the demonstration that domains 2 
and 3 can readily fold when up to three amino-acids are removed from the linker 
region implies a more open association between these domains. This is reminiscent of 
the 4 domain tandem structure of CD448 where domains 1 and 2 are tightly associated, 
as are domains 3 and 4, whereas an extended linker at the domain 2/domain 3 
interface leads to molecular flexibility at this junction. Similarly, CD2, which has a 4 
amino-acid linker between IgSF domains 1 and 2, is also believed to undergo hinge 
bending shifts affecting domain orientation49 and exposing a buried antibody epitope 
during T-cell activation50. In Lu gp, it is unclear whether the potential flexibility this 
extended linker may generate is essential for Ln binding. Nonetheless, the 
demonstration that the binding site straddles the adjacent ends of D2 and D3 implies 
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that only a discrete arrangement of the domains would form a coherent binding site; 
variations from this position would be expected to be deleterious for Ln binding. The 
assumption that the D2/D3 boundary is a source of flexibility therefore suggests an 
association between these movements and effective Ln binding. A precedent for this 
proposed mechanism is provided by the killer cell inhibitory receptors in which a 
linker region between two IgSF domains forms the MHC binding interface, with 
binding modulated by differences in the relative domain orientations51. The potential 
for domain-domain movement within Lu gp provides a possible explanation for the 
increase in adhesion to Ln511/521 observed in cells expressing Lu gp in response to 
‘inside-out’ signalling events13-15. 
 
A common feature of cell-cell adhesion pairs for which structures are available is the 
exploitation of the broad faces presented by amino-terminal IgSF domains (usually 
formed by the C”C’CFG sheet) to generate extensive contact surfaces52. These are 
typified in the CD2:CD58 pair26 where some 1200 Å2 of surface area are buried in a 
relatively flat interface within the complex. A recent exception is the SIRPα receptor 
which instead uses the complementarity-determining loop regions as the adhesion 
site, although these are at the amino terminal end of the receptor and assumed to be 
furthermost from the cell membrane52. Nonetheless, these and similar electrostatic 
interactions frequently generate only low-affinity binding. The Lu gp:Ln511/521 
interaction differs substantially. The data presented here show this to be a high-
affinity (KD ~ 10 nM) interaction arising from a cluster of residues contributed from 
adjacent loop regions of two domains. It is feasible that enclosure of the ligand 
through domain movements may contribute to the slow off-rate of the complex. 
Indeed the Lu gp point mutations constructed in this study seemed only to have an 
effect on the on-rate of Ln binding and not the off rate (Figure 3d). Unlike many cell 
adhesion molecules, the binding surfaces in Lu gp are not located on the amino-
terminal domain which would be most distal from the cell surface in the tandem 
arrangement implied by the overall shape of Lu gp (D1-D5). Access to the binding 
site would therefore either require interdigitation of extended Ln and Lu gp proteins 
when cells are located on the ECM or, alternatively, considerable flexing of Lu gp at 
the D2/D3 boundary in order to present the binding surface to the ligand. The 
extended structure observed for D1-D5 suggests that Lu gp does not adopt a compact 
structure akin to the horseshoe arrangement observed in both axonin53 and hemolin54 
which could place the D2/D3 boundary furthermost from the cell surface. The 
predominance of sites for Lutheran blood group antigens on all faces of D1 and D2 
(Figure 1c) also implies that these domains are fully exposed at the erythrocyte 
surface, again inconsistent with a compact structure. The angle generated by the D2-
D3 junction as described in this study may promote interactions between the D1D2 
fragment and other ECM components. This angle is similar to that observed between 
the IgSF domains 2 and 3 of the neural cell adhesion molecule NCAM, for which a 
heparin binding site has also been located to domain 255. There is currently no 
evidence, however, that Lu gp can undergo the zipper-like formation of homophilic 
interactions described for NCAM to build multi-molecular adhesion complexes.  
 
Our findings provide clear evidence that Lu gp interaction with the Ln α5 chain is 
mediated by a negatively charged patch on the tip of Lu gp extracellular D3 and base 
of D2 in a manner analogous to that occurring for the other ligands of Ln, heparin and 
α-dystroglycan. In this case, the negatively charged patch is composed of glutamic 
and aspartic acid residues rather than sulphated sugars. Our results further suggest that 
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the Ln511/521 binding site on Lu gp is located at a potentially flexible interdomain 
linker region and it is possible that the amino-terminal D1 and D2 may be required to 
fold back to expose the binding site for Ln511/521. Confirmation of this mechanism 
awaits further structural analysis of Lu gp and identification of the Lu gp binding site 
in the LG1-3 region of the Ln α5 chain. Nevertheless these findings pave the way for 
development of inhibitors of the Lu gp:Ln511/521 interaction and thereby potential 
novel therapies ameliorating vasocclusion in sickle cell disease. 
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Wavelength (Å) 1.488 1.285 1.01 1.042 1.071 1.08 
Spacegroup P3221 P21 P21 P21 P21 P21 
Resolution range 
(Å) 
44.6 – 2.2 
(2.28 – 2.2) 
35.3 – 1.7 
(1.76 – 1.7) 
35.7 – 1.8 
(1.86 – 1.8) 
35.7 – 1.8 
(1.86 – 1.8) 
36.1 – 2.5 
(2.59 – 2.5) 
33.5 – 2.5 
(2.59 – 2.5) 
Redundancy 5.6 (1.8) 6.4 (2.0) 8.6 (2.7) 8.9 (3.3) 6.8 (3.0) 5.9 (1.8) 
Completeness 90.1 (41.3) 89.1 (48.3) 89.5 (50.3) 90.5 (49.6) 93.6 (70.3) 85.4 (32.6) 
Rmerge 10.2 (48.2) 5.9 (26.4) 9.8 (23.3) 6.9 (20.0) 11.8 (26.3)) 8.9 (32.6 




  0.51 / 0.65 0.52 / 0.67 0.85 / 0.91 0.87 / 0.92 
Anomalous Rcullis 
  0.83 0.88 0.95 0.97 
Initial Phase 
Figure-of-Merit 
 0.73     
Unique reflections 18741 23563     
Rwork 0.205 0.168     
Rfree 0.251 0.21     
Non-H atoms 3643 2096     
Bond Length 
RMSD (Å) 0.018 0.015 
    
Bond Angle RMSD 
(°) 1.498 1.678 
    
 
Table 1: Diffraction data processing and refinement statistics for D1D2 crystal forms. 




Figure 1. Structure of Lu gp D1D2. (a) Cartoon representation in stereo showing the 
Lu gp structure. D1 is shown at the top and D2 at the bottom. The strands in each 
domain are labelled, as are the amino (N) and carboxy termini (C). (b) Overlay of Cα 
traces from the three independent copies of D1D2 in the two crystal structures. 
Orientation is as in (a). (c) Location of residues that are altered in the known inherited 
forms of Lu gp that can be attributed to D1D2. Mutated residues are shown in stick 
form, and are coloured as follows: Lu a/b – red, Lu4 – purple, Lu5 – yellow, Lu8/14 – 
blue, Lu12 – pink, Lu16 –grey and Lu17 – orange. 
 
Figure 2. SAXS analysis of Lu gp D1D2D3. (a) Experimental scattering data for Lu 
gp D1D2D3 plotted in black as a function of q and compared with a theoretical fit 
generated with SASREF47. (b) Shapes obtained using a bead model using the program 
GASBOR46 from 20 independent simulations, each differently coloured. The average 
shape is shown as orange wire-frame density in: (c) Representative rigid-body fit of 
the D1D2 crystal structure and D3 model to the scattering data, overlaid on average 
density obtained as in (b). D1 is shown in blue, D2 in green and D3 in red. (d) Shapes 
obtained from the scattering curve for Lu gp (D1-D5) as described in (b). The average 
shape is shown as orange wire-frame density in: (e) Overlay of the D1D2D3 model on 
the envelope derived for Lu gp (D1-D5). D4 and D5 are expected to occupy the 
additional density at the base of the figure, proximal to the cell membrane. 
 
Figure 3. Mutation of acidic residues of Lu gp reduces Ln511/521 binding. (a) 
Representative ELISA titrations of 5, 0.5, 0.05 and 0.005nM Lu gp binding to 5nM 
Ln511/521 for the E309A, D310A, D312A and D315A (solid line) mutations in 
comparison to native Lu gp (dashed line). Standard deviation for each point is under 
0.1. ELISA results of all other mutations can be seen in Supplementary Data 4. (b) 
The level of binding to Ln511/521 of mutant Lu gp compared with the native protein 
at 0.05nM measured in an ELISA. Proteins were assayed in duplicate and the results 
shown are the mean of two separate ELISA plates and are expressed as the percentage 
of the absorption seen from wells containing native Lu gpFc (OD450=0.95). (c) 
Ln511/521 binding assessed by surface plasmon resonance using a BiacoreX. Shown 
is the mean change in response units (RU) over the course of a 100µl injection of 
10nM Ln511/521 for two assays per protein. In both (b) and (c) Ln511/521 binding to 
Muc18 acted as a negative control. (d) Overlaid sensorgrams for a representative 
sample of the different proteins showing the association and dissociation curves of 
Ln511/521 binding to Lu gpFc. Vertical arrows indicate the beginning and end points 
of the Ln511/521 injection. 
 
Figure 4. Location of charged amino-acid residues involved in interactions with 
Ln511/521 on the surface of Lu gp. (a) Lu gp domains D1D2 (dark grey) and D3 
(light grey) are shown in an orientation consistent with the SAXS envelope. Indicated 
are the positions of acidic residues that have been mutated to alanine. The residues are 
colour coded according to their effect on Ln511/521 binding; Blue - No effect, 
Yellow - slight effect, Orange - marked effect and Red - severe effect. (b) Lu 
D1D2D3 in the same orientation, shown as an electrostatic surface. 
 
Figure 5. Ln511/521 binding to D2-D3 linker mutants.  
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(a) Three proteins, T233P, H235P and ∆233-235 (darker shade), containing mutations 
within the domain 2 to 3 hinge were made. (b) Representative ELISA titration's of 
hinge region mutants to Ln511/521 in comparison to binding to the native protein. 
Standard deviations were less than 0.1 OD units for any point. (c) The sensorgrams of 





































































Supplementary Data 1 
 
Small-Angle X-ray scattering analysis – Full method 
 
SAXS data of D1D2D3 were collected on beamline X33 at the European Molecular 
Biology Laboratory (EMBL) of the Deutsches Elektronen Synchrotron (DESY) using 
a wavelength of λ = 0.15 nm. The sample to detector distance was 2.4 m, covering a 
scattering range of 0.16 nm-1 < q < 4.85 nm-1. The modulus of the scattering vector is 
defined as q = 4π sinθ/λ, where 2θ is the scattering vector. SAXS data were collected 
from D1D2D3 at concentrations of 4.375 mg/ml, 8.75 mg/ml and 17.5 mg/ml; 
samples were exposed for 60s. 1mM dithiothreitol was added to each concentration of 
D1D2D3 solution before data collection to minimise aggregation. The scattering 
images were integrated to one-dimensional linear profiles using in-house software at 
station X33. Scattering data from the corresponding buffer were collected and 
subtracted from the sample data in order to remove background scattering. This was 
achieved using PRIMUS1. The corrected data at each concentration were then merged 
together using PRIMUS. GNOM, the indirect Fourier transform program2 was then 
applied to evaluate the particle distance distribution function, p(r), and the radius of 
gyration, Rg. The shape of the protein was evaluated from the scattering data using 
the programs DAMMIN3 and GASBOR4, which are applications that use ab initio 
procedures to build models of proteins using simulated annealing. Twenty simulations 
were performed with each program, and the structures generated were averaged using 
DAMAVER5. Rigid-body modelling used the three unique crystallographically 
determined structures of D1D2, the D3 homology model and carbohydrate fragments 
extracted from PDB 1L6X. These were fitted to the scattering data with the program 
SASREF6, theoretical scattering curves for each rigid body being computed with 
CRYSOL7. 
 
SAXS measurements of the entire extracellular portion of Lu (D1-D5) were obtained 
on a modified version of the commercially available NanoSTAR (Bruker AXS, 
Karlsruhe) X-ray facility at the University of Aarhus. Further details about the 
modified NanoSTAR are given in8. Data were collected at a concentration of 15 
mg/ml, and were exposed for 1 hour. Data collection was conducted at 4°C in a re-
usable thermostated quartz capillary, which is mounted in an in-house built capillary 
holder with good thermal contact to the thermostated surrounding block. The capillary 
holder was then positioned in the vacuum chamber. The sample to detector distance 
was 65 cm, covering a scattering range of 0.085 < q < 3.5 nm–1. The scattering data 
were corrected for variations in detector efficiency and spatial distortions. The two-
dimensional data were azimuthally averaged to one-dimensional linear profiles using 
Bruker SAXS software for Windows™ NT. Using in-house software at the University 
of Aarhus, the scattering data from the corresponding buffer were subtracted from the 
sample data, and the scattering intensities were transformed to absolute units using the 
scattering of water as a standard. Ab initio shape reconstruction was performed as 
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Supplementary Data 2 Sequence of Lu gp D1D2. The β-strands observed in the 
crystal structure are indicated by shaded boxes and labeled with bold letters. Mutated 








Supplementary Data 3 Western blots using Bric 224 (a) followed by a rabbit anti-
mouse HRP secondary Ab was performed on non-reduced samples (0.2µgs) and using 
a anti human Fc HRP conjugate. Lanes are i-E132A/D133A, ii-E180A, iii-
D198A/D199A, iv E234A, v-D269A, vi-D280A, vii-D281A, viii- E309A, ix- E310A, 
x- D312A, xi- D315A, xii- D316A and xiii- Native Lu. Non- reduced Western blots 
using Bric 224 (b) of ∆233-235 (i), T233P (ii) H235P (iii), linker mutations and native 







Supplementary Data 4 
Representative ELISA titration's of 5, 0.5, 0.05 and 0.005nM Lu gp binding to 5nM 
Ln511/521 for the Mutated Lu gpFc (Blue) mutations in comparison to native Lu gp 
(Magenta). Standard deviation for each point is under 0.1. 
 
 
 
